Mira Dx, Inc.

New Haven, CT · Founded 2008 · CIK 0001471338 · Biotech · Private

Genetic biomarkers for predicting cancer treatment toxicity and efficacy

miradx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$2.1M
1 Form D · Sep 2009
205 months since last filing
Contracts
—
No federal contracts on record
Patents
11
3 granted · 8 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,088,459
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2546Regenerate, Inc.—$2.3M
2547ANAGIN—$2.3M
2548Amplo Biotechnology, Inc.—$2.2M
2549Mira Dx, Inc.—$2.1M
2550CellVax Therapeutics, Inc.—$2.1M
2551BACTRIA PHARMACEUTICALS LLC——
2552Regenimo Biosciences, Inc.—$2.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Barbara Mignogna-KorusDirector · Executive Officer
  • Stephen MillerDirector · Executive Officer
  • Mary PolanDirector
  • Andrew WeidhaasDirector · Executive Officer

Patents

USPTO · 3 granted of 11

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.